IRONWOOD PHARMACEUTICALS INC 8-K

What Happened
Ironwood Pharmaceuticals, Inc. notified Wells Fargo Bank, N.A., as administrative agent, on March 10, 2026 that it satisfied the liquidity conditions set forth in the definition of “Maturity Date” under its Credit Agreement (dated May 21, 2023, as amended September 27, 2024). The company filed an 8‑K on March 11, 2026 reporting this event. As a result, the maturity date for the revolving credit facility under the Credit Agreement remains December 31, 2028, subject to the other terms and conditions of the Credit Agreement.

Key Details

• Notice sent March 10, 2026 to Wells Fargo Bank, N.A., acting as administrative agent.
• Credit Agreement originally dated May 21, 2023; amended by Amendment No. 1 on September 27, 2024.
• Company confirmed it “satisfied the liquidity conditions” in the definition of “Maturity Date.”
• Revolving credit facility maturity remains December 31, 2028 (no change reported to other terms).

Why It Matters
This is a liquidity/legal update, not an earnings or management change. By confirming the liquidity conditions were met and the maturity date remains Dec. 31, 2028, Ironwood signals that, as of the notice date, it retained the contractual timeline for its revolving credit facility. For investors, this preserves the company’s access to the agreed revolving credit through 2028 under existing terms and reduces immediate refinancing date uncertainty; it does not announce new borrowing, amendments, or other material changes.